|
Product Name
|
|
Zika Virus Envelope, Monoclonal Antibody ★Popular Item★
|
Also Known As
|
|
Human Anti-Zika Virus Envelope (EIII Domain) (ZIKV E Protein)
|
Research Use Only
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
TOP
|
|
Clonality
|
|
Monoclonal
|
Isotype
|
|
IgG1,k
|
Clone Number
|
|
ZKA64
|
Host
|
|
Human
|
|
Specificity
|
|
Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E).
|
Purity/Purification
|
|
> or = 98% by SDS-PAGE).
|
Form/Format
|
|
Supplied as a liquid in PBS. No preservative added.
|
Concentration
|
|
1mg/ml (lot specific)
|
|
Endotoxin
|
|
<0.001EU/ug
|
Immunogen
|
|
EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naive human donors.
|
Note
|
|
Preservative Free
|
|
Preparation and Storage
|
|
May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
|
Other Notes
|
|
Small volumes of anti-Zika Virus Envelope antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
|
TOP
|
|
|
|
The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry; EDII containing the fusion loop; and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
|
|
Application Notes for anti-Zika Virus Envelope antibody
|
|
Suitable for use in Neutralization. Other applications not tested.
Neutralization: Neutralizes Zika Virus (ZIKV) with an IC50 of ~93ng/ml. Also enhances ZIKV infection in non-permissive K562 cells at a broad range of concentrations (not above 1ug/ml). Optimal dilutions to be determined by the researcher.
|
|
Zika rash of anti-Zika Virus Envelope antibody
|
|
Arm
|
|
Aedes aegypti Image source of anti-Zika Virus Envelope antibody
|
|
Centers for Disease Control and Prevention Public Health Image Library
|
TOP
|
|
|
|
1. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection: K. Stettler, et al.; Science 353, 823 (2016).
|
|
TOP
|
Precautions
|
|
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
|
Disclaimer
|
|
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
|
TOP
|